Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
MWN-AI** Summary
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company dedicated to advancing safe and effective cell therapies for severe autoimmune diseases and cancers, recently announced its participation in the TD Cowen 46th Annual Health Care Conference. Scheduled for March 4, 2026, at 1:10 p.m. EST in Boston, MA, the event will feature a fireside chat with Artiva's management team. Investors attending the conference will also have opportunities for one-on-one meetings with executives.
Artiva's lead therapy, AlloNK® (AB-101), is an innovative allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy. It's designed to enhance the effectiveness of monoclonal antibodies in promoting B-cell depletion, which is crucial for treating B-cell driven autoimmune diseases. The company is actively conducting three clinical trials that encompass a range of autoimmune disorders, including rheumatoid arthritis and Sjögren’s disease.
Founded in 2019 as a spin-off from GC Cell in South Korea, Artiva holds exclusive worldwide rights to GC Cell's NK cell manufacturing technology and programs, excluding specific regions in Asia and Oceania. The company is headquartered in San Diego, California, and continues to explore innovative therapies, including CAR-NK candidates aimed at treating both solid and hematologic cancers.
For those interested in Artiva's developments, the audio webcast of the conference and other presentations will be accessible through the Investors section of their website, with replays available for 90 days. As the company progresses, it remains committed to transparency and compliance, urging caution regarding forward-looking statements concerning its future endeavors.
MWN-AI** Analysis
As Artiva Biotherapeutics prepares for participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 4, 2026, investors should closely monitor the implications of this event on the company’s stock performance. Artiva, recognized for its innovative work in cell therapies targeting autoimmune diseases and cancers, is at a pivotal moment as it advances its lead program, AlloNK® (AB-101), through several clinical trials.
Artiva’s focus on developing effective off-the-shelf NK cell therapies presents significant opportunities in the burgeoning immunotherapy market. As healthcare investors should be aware, the growth of this sector is underpinned by increasing demand for targeted therapies, which may position Artiva advantageously as it progresses in clinical evaluations, particularly for B-cell driven autoimmune diseases.
During the conference, insights into the ongoing trials and future strategic directions will likely be highlighted. This could provide valuable indicators regarding the company's potential market trajectory. Given the favourable response to innovative treatment modalities in the biotech sector, positive updates could catalyze upward momentum in ARTV shares. However, investors should remain cautious, taking into account the inherent risks associated with clinical-stage biotech investments, including trial results, regulatory approvals, and funding requirements.
Artiva's partnership with GC Cell and its unique NK cell manufacturing technology presents a competitive edge not easily replicated. This aspect warrants further investigation by investors eager to assess the company's integrity and potential for sustainable growth.
In summary, closely watching Artiva Biotherapeutics during the TD Cowen Conference could yield insights into its future viability. However, it is crucial for investors to balance enthusiasm with a critical evaluation of the company's inherent risks, aligning their investment strategies accordingly.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.
Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference.
To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
FAQ**
What strategic updates regarding Artiva Biotherapeutics Inc. (ARTV) are anticipated during the fireside chat at the TD Cowen 46th Annual Health Care Conference?
How does Artiva Biotherapeutics Inc. (ARTV) plan to address the ongoing clinical trials for its AlloNK® therapy in the context of its overall pipeline?
Can the management of Artiva Biotherapeutics Inc. (ARTV) provide insights into the expected impact of their partnerships on future research and development initiatives?
What key performance metrics should investors look for to gauge the success of Artiva Biotherapeutics Inc. (ARTV) in the upcoming clinical trial results?
**MWN-AI FAQ is based on asking OpenAI questions about Artiva Biotherapeutics Inc. (NASDAQ: ARTV).
NASDAQ: ARTV
ARTV Trading
7.12% G/L:
$5.925 Last:
50,152 Volume:
$5.72 Open:
